Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-24 @ 11:37 PM
NCT ID:
NCT01915056
Eligibility Criteria:
Inclusion Criteria:
* Have a diagnosis of solid tumor malignancy or lymphoma
* Have advanced cancer
* Have received a recommendation for first or second line treatment with chemotherapy by their primary oncologist. Treatment regimens may include chemotherapy, chemoradiotherapy, targeted agents or monoclonal antibody.
* Planned chemotherapy for at least 3 months
* Be age 70 or older
* Have a live expectancy with treatment of 6 months or greater
* Able to provide informed consent or, if the physician deems the patient to not have decision-making capacity, a patient-designated health care proxy (that was pre-existing; prior to the patient losing decision-making capacity) must sign consent per institutional (University of Rochester and Research Subject Review Board) policies on consent for incapacitated/decisionally impaired subjects164,165
* Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)
Exclusion Criteria:
* Have surgery planned within 3 months of consent
* Have a planned referral to the geriatric oncology clinic within one month of treatment initiation
* Patients who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
70 Years
Study:
NCT01915056
Study Brief:
Protocol Section:
NCT01915056